在Sjögren综合征的新和潜在的未来治疗选择
Ting Zhao1,2, Runrun Zhang2, Zhaofu Li1
1Key Laboratory of Traditional Chinese Medicine for Prevention and Treatment of Neuropsychiatric Diseases, Yunnan University of Chinese Medicine, Kunming, 650500, China.
Heliyon
|October 21, 2024
概括
对于Sjögren的新疗法
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 再生医学是一种再生医学.
背景情况:
- 肖格伦综合征 (SS) 是一种慢性自身免疫性疾病,影响外分泌腺.
- 目前的SS治疗主要是治疗症状,而不是自身免疫原因.
- 对Sjögren综合征的治疗选择有限.
研究的目的:
- 审查Sjögren综合征的前沿治疗策略.
- 探索针对SS的向治疗和再生医学方面的进展.
- 突出SS的创新治疗范式.
主要方法:
- 对SS的临床和临床前药物的审查.
- 对针对自身免疫路径的新兴生物疗法的分析.
- 评估再生医学方法,包括干细胞治疗.
主要成果:
- 生物药物在SS.中提供针对性抑制细胞因子和细胞表面分子.
- 干细胞治疗显示出恢复唾液和眼腺功能的潜力.
- 进步促进了针对SS的向治疗的发展.
结论:
- 对于Sjögren综合征,新的治疗策略正在出现.
- 向治疗和再生医学为SS患者提供了新的希望.
- 创新正在推动SS的先进治疗模式的发展.
相关概念视频
Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K
Nephrotic Syndrome II : Assessment and Medical Management
1
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
1
Inflammatory Bowel Disease IV: Pharmacological Management
117
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
117
Autoimmune Disorders
390
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
390
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
258
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
258


